Aspirin versus clopidogrel monotherapy after dual antiplatelet therapy in coronary artery disease: a systematic review and meta-analysis
Annals of Middle Eastern Medicine · 23.10.2026 · 2 (5) · 636-644
DOI: 10.24911/amem.15-3129 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Annals of Middle Eastern Medicine, online erschienen am 23.10.2026. Verfasst von Saud Ali Almutairi und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Aspirin has traditionally been the standard antiplatelet therapy after discontinuation of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention. However, emerging evidence suggests that clopidogrel may offer comparable or potentially better outcomes. This study compared the efficacy and safety of aspirin versus clopidogrel monotherapy in patients with coronary artery disease (CAD).
Methods
We performed a systematic review and meta-analysis in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The protocol was registered in the International Prospective Register of Systematic Reviews (CRD420251101793). PubMed, Google Scholar, and the Cochrane Library were searched from inception to August 2025 for randomized controlled trials and observational studies comparing aspirin with clopidogrel monotherapy after DAPT. Outcomes included myocardial infarction (MI), stroke, major and minor bleeding, cardiovascular mortality, revascularization, and stent thrombosis. Risk ratios (RRs) with 95% confidence intervals (CIs) were pooled using a random-effects model.
Results
Seven studies involving more than 15,000 patients were included. Aspirin was associated with a significantly higher risk of stroke than clopidogrel (RR 1.51, 95% CI: 1.06-2.15, p = 0.024). No significant differences were observed in MI (RR 1.06, 95% CI: 0.74-1.53, p = 0.738), major bleeding (RR 1.16, 95% CI: 0.78-1.75, p = 0.463), minor bleeding (RR 1.43, 95% CI: 0.72-2.82, p = 0.304), cardiovascular mortality (RR 1.14, 95% CI: 0.87-1.50, p = 0.331), revascularization (RR 1.07, 95% CI: 0.91-1.27, p = 0.401), or stent thrombosis (RR 1.53, 95% CI: 0.81-2.89, p = 0.193).
Conclusion
Clopidogrel and aspirin showed no significant differences in most evaluated outcomes after DAPT. Clopidogrel was associated with a lower risk of stroke without a significant increase in major or minor bleeding, supporting its use as an alternative to aspirin for long-term maintenance therapy.
Zitieren
APA
Almutairi, S. A., Alruwaili, Y. M., Alwaily, H. M., Alhafi, T. A., Altuwaijri, H. Y., Alhamoud, M. A., & Alghadeer, S. A. (2026). Aspirin versus clopidogrel monotherapy after dual antiplatelet therapy in coronary artery disease: a systematic review and meta-analysis. Annals of Middle Eastern Medicine, 2(5), 636-644. https://doi.org/10.24911/amem.15-3129
Vancouver
Almutairi SA, Alruwaili YM, Alwaily HM, Alhafi TA, Altuwaijri HY, Alhamoud MA, et al. Aspirin versus clopidogrel monotherapy after dual antiplatelet therapy in coronary artery disease: a systematic review and meta-analysis. Annals of Middle Eastern Medicine. 2026;2(5):636-644. doi:10.24911/amem.15-3129
BibTeX
@article{Almutairi2026,
author = {Almutairi, Saud Ali and Alruwaili, Yazeed Mohammed and Alwaily, Hussam Mohammed and Alhafi, Tariq Abdullah and Altuwaijri, Hussam Yousef and Alhamoud, Mohammad Abdulsamad and Alghadeer, Saleh Abdulaziz},
title = {Aspirin versus clopidogrel monotherapy after dual antiplatelet therapy in coronary artery disease: a systematic review and meta-analysis},
journal = {Annals of Middle Eastern Medicine},
year = {2026},
volume = {2},
number = {5},
pages = {636--644},
doi = {10.24911/amem.15-3129}
}
EUVIMED